Interview with the President and CEO: Soligenix, Inc. (OTCBB:SNGX)

Healthcare >> CEO Interviews >> October 23, 2015

Christopher J. Schaber, Ph.D., is President and Chief Executive Officer of Soligenix, Inc. He has over 25 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been President and Chief Executive Officer and a director of Soligenix (OTCBB:SNGX) since August 2006. He was appointed Chairman of the board on October 8, 2009. He also serves on the board of directors of the Biotechnology Council of New Jersey — BioNJ — since January 2009 and the Alliance for Biosecurity since October 2014, and has been a member of the corporate councils of both the National Organization for Rare Diseases — NORD — and the American Society for Blood and Marrow Transplantation — ASBMT — since October 2009 and July 2009, respectively. Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, Dr. Schaber was a Co-Founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his B.A. degree from Western Maryland College, his M.S. degree in pharmaceutics from Temple University School of Pharmacy and his Ph.D. degree in pharmaceutical sciences from the Union Graduate School. Profile

TWST: Can you describe your company and its purpose?

Dr. Schaber: Our company’s tagline concisely describes its purpose, and that is: rising to the challenges of rare disease

Join for free to read a longer excerpt or purchase this article

Interview with the President and CEO: Soligenix, Inc. (OTCBB:SNGX)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the President and CEO: Soligenix, Inc. (OTCBB:SNGX)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS